Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For type 2 diabetes mellitus. Sold as Ozempic, Rybelsus, Wegovy, Wegovy Hd, Wegovy Flextouch. Every FDA application for this active ingredient: 5 branded and 1 generic.
As of Nov 15, 2026, FDA lists 6 applications for Semaglutide (sold as Ozempic, Rybelsus, Wegovy and others), first approved Dec 5, 2017, with 12 new uses approved and 0 published complete response letters.
First approved: Dec 5, 2017
Applications: 6
New uses approved: 12
Complete response letters: 0
Medicare spending, 2025: $19.2B
First approved in the EU: Feb 8, 2018
First approved in Japan: Mar 23, 2018
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 4 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Wegovy, new approval(1) Drugs with a new indication, a new dosage and other characteristics for the treatment of obesity. · Novo Nordisk Pharma Ltd. · Mar 27, 2023 · Review report
Rybelsus, new approvalDrugs with a new route of administration indicated for the treatment of type 2 diabetes mellitus. · Novo Nordisk Pharma Ltd. · Jun 29, 2020
Ozempic, new ingredientA drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. · Novo Nordisk Pharma Ltd. · Mar 23, 2018
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
